FOLH1 and Familial prostate cancer: PSMA PET/CT can identify soft tissue disease not seen with anatomical imaging (e.g. metastatic nodes that are not pathologically enlarged) or bone scanning (bone metastases that have not elicited a sclerotic response), thus improving accuracy in prostate cancer staging and detection of metastases [29–31].